<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01033942</url>
  </required_header>
  <id_info>
    <org_study_id>ATN 082</org_study_id>
    <nct_id>NCT01033942</nct_id>
  </id_info>
  <brief_title>Pre-Exposure Prophylaxis in YMSM</brief_title>
  <official_title>Acceptability and Feasibility of a Pre-Exposure Prophylaxis (PrEP) Trial With Young Men Who Have Sex With Men (YMSM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory mixed-methods research study that compares an efficacious behavioral
      HIV-prevention intervention (3MV) alone to the behavioral HIV-prevention intervention
      combined with a biomedical intervention (PrEP). After completing the 3MV behavioral
      intervention, participants will be randomly assigned to one of three study arms: 1) daily
      FTC/TDF as PrEP, 2) placebo pill control, or 3) &quot;no pill&quot; control. Behavioral and biomedical
      data will be collected at baseline and every 4 weeks thereafter for 24 weeks. Youth who
      decline to participate will be asked to complete a brief survey about their opinions on PrEP.
      Qualitative interviews will be completed with six study participants and the study
      coordinators at the end of the trial to explore further the issues of trial acceptability and
      feasibility. Finally, focus groups will be conducted to explore feasibility and acceptability
      issues with YMSM who meet all eligibility requirements of the study except for not being age
      18 or older, but are at least 16 years of age.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Actual Number of Study Visits Completed by 24 Weeks</measure>
    <time_frame>24 weeks</time_frame>
    <description>This outcome measure looked at whether the actual number of study visits conducted by 24 weeks differed by treatment group over time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acceptability of Size of Pill</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Acceptability of the Taste of the Pill</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Acceptability of the Color of the Pill</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Acceptability of Taking the Pill Everyday</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Acceptability of Taking Part in the Study</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Acceptability of Participating in Group Sessions</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Acceptability of Being Randomly Assigned to a Group</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Acceptability of Having an HIV Test at Every Visit</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Acceptability of Risk Reduction Counseling at Every Visit</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Acceptability of Questions About Sexual Behavior at Every Visit</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Acceptability of Being Contacted by the Research Team in Between Visits</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Acceptability of Physical Examination by a Doctor</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Acceptability of Health Clinic for Study Visits</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Missed Doses Based on Self-Report Calendar Data-Week 4</measure>
    <time_frame>4 weeks</time_frame>
    <description>Missed doses were calculated as the number of days between the date that subject came in for their current visit and the last date the subject was dispensed medication minus the total number of days the subject records having taken their medication in the last 31 days based on self-report calendar data. Since each subject is given a 30 day supply of medication at each visit, any days after 30 days are assumed to be missed medication days and are included in the total. Participants were taking only one dose per day and thus, the number of missed doses is the same as the number of missed medication days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Missed Doses Based on Self-Report Calendar Data-Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Missed doses were calculated as the number of days between the date that subject came in for their current visit and the last date the subject was dispensed medication minus the total number of days the subject records having taken their medication in the last 31 days based on self-report calendar data. Since each subject is given a 30 day supply of medication at each visit, any days after 30 days are assumed to be missed medication days and are included in the total. Participants were taking only one dose per day and thus, the number of missed doses is the same as the number of missed medication days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Missed Doses Based on Self-Report Calendar Data-Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Missed doses were calculated as the number of days between the date that subject came in for their current visit and the last date the subject was dispensed medication minus the total number of days the subject records having taken their medication in the last 31 days based on self-report calendar data. Since each subject is given a 30 day supply of medication at each visit, any days after 30 days are assumed to be missed medication days and are included in the total. Participants were taking only one dose per day and thus, the number of missed doses is the same as the number of missed medication days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Missed Doses Based on Self-Report Calendar Data-Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>Missed doses were calculated as the number of days between the date that subject came in for their current visit and the last date the subject was dispensed medication minus the total number of days the subject records having taken their medication in the last 31 days based on self-report calendar data. Since each subject is given a 30 day supply of medication at each visit, any days after 30 days are assumed to be missed medication days and are included in the total. Participants were taking only one dose per day and thus, the number of missed doses is the same as the number of missed medication days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Missed Doses Based on Self-Report Calendar Data-Week 20</measure>
    <time_frame>Week 20</time_frame>
    <description>Missed doses were calculated as the number of days between the date that subject came in for their current visit and the last date the subject was dispensed medication minus the total number of days the subject records having taken their medication in the last 31 days based on self-report calendar data. Since each subject is given a 30 day supply of medication at each visit, any days after 30 days are assumed to be missed medication days and are included in the total. Participants were taking only one dose per day and thus, the number of missed doses is the same as the number of missed medication days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Missed Doses Based on Self-Report Calendar Data-Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Missed doses were calculated as the number of days between the date that subject came in for their current visit and the last date the subject was dispensed medication minus the total number of days the subject records having taken their medication in the last 31 days based on self-report calendar data. Since each subject is given a 30 day supply of medication at each visit, any days after 30 days are assumed to be missed medication days and are included in the total. Participants were taking only one dose per day and thus, the number of missed doses is the same as the number of missed medication days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Missed Doses Over Time Based on Self-Report Calendar Data</measure>
    <time_frame>24 weeks</time_frame>
    <description>The outcome measure presents the least square means from the generalized linear model. The outcome here is a binary variable that determines whether the subject missed a dose or not. In a binomial model with logit link, the least squares means are predicted population margins of the logits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Missed Doses Based on Medication Refill Dates-Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Missed doses were calculated as the number of days between the actual and expected refill dates. Participants were taking only one dose per day and thus, the number of missed doses is the same as the number of missed medication days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Missed Doses Based on Medication Refill Dates-Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Missed doses were calculated as the number of days between the actual and expected refill dates. Participants were taking only one dose per day and thus, the number of missed doses is the same as the number of missed medication days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Missed Doses Based on Medication Refill Dates-Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Missed doses were calculated as the number of days between the actual and expected refill dates. Participants were taking only one dose per day and thus, the number of missed doses is the same as the number of missed medication days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Missed Doses Based on Medication Refill Dates-Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>Missed doses were calculated as the number of days between the actual and expected refill dates. Participants were taking only one dose per day and thus, the number of missed doses is the same as the number of missed medication days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Missed Doses Based on Medication Refill Dates-Week 20</measure>
    <time_frame>Week 20</time_frame>
    <description>Missed doses were calculated as the number of days between the actual and expected refill dates. Participants were taking only one dose per day and thus, the number of missed doses is the same as the number of missed medication days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Missed Doses Based on Medication Refill Dates-Overall</measure>
    <time_frame>20 Weeks</time_frame>
    <description>Missed doses were calculated as the number of days between the actual and expected refill dates. Participants were taking only one dose per day and thus, the number of missed doses is the same as the number of missed medication days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Tenofovir Plasma Concentrations (mg/mL) Detected at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Subjects reporting tenofovir is calculated as those subjects that had a tenofovir plasma concentration greater than zero (BLQ). Subjects with BLQ+ (&lt;10 ng/mL) were included in this count.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Tenofovir Plasma Concentrations (mg/mL) Detected at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Subjects reporting tenofovir is calculated as those subjects that had a tenofovir plasma concentration greater than zero (BLQ). Subjects with BLQ+ (&lt;10 ng/mL) were included in this count.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Tenofovir Plasma Concentrations (mg/mL) Detected at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Subjects reporting tenofovir is calculated as those subjects that had a tenofovir plasma concentration greater than zero (BLQ). Subjects with BLQ+ (&lt;10 ng/mL) were included in this count.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Tenofovir Plasma Concentrations (mg/mL) Detected at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Subjects reporting tenofovir is calculated as those subjects that had a tenofovir plasma concentration greater than zero (BLQ). Subjects with BLQ+ (&lt;10 ng/mL) were included in this count.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Tenofovir Plasma Concentrations (mg/mL) Detected at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>Subjects reporting tenofovir is calculated as those subjects that had a tenofovir plasma concentration greater than zero (BLQ). Subjects with BLQ+ (&lt;10 ng/mL) were included in this count.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Tenofovir Plasma Concentrations (mg/mL) Detected at Week 20</measure>
    <time_frame>Week 20</time_frame>
    <description>Subjects reporting tenofovir is calculated as those subjects that had a tenofovir plasma concentration greater than zero (BLQ). Subjects with BLQ+ (&lt;10 ng/mL) were included in this count.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Tenofovir Plasma Concentrations (mg/mL) Detected at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Subjects reporting tenofovir is calculated as those subjects that had a tenofovir plasma concentration greater than zero (BLQ). Subjects with BLQ+ (&lt;10 ng/mL) were included in this count.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Missing Study Pills Because Participant Was Away From Home</measure>
    <time_frame>24 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Missing Study Pills Because Participant Was Too Busy With Other Things</measure>
    <time_frame>24 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Missing Study Pills Because Participant Simply Forgot</measure>
    <time_frame>24 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Missing Study Pills Because Participant Had Too Many Study Pills to Take</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Missing Study Pills Because Participant Wanted to Avoid Side Effects</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Missing Study Pills Because Participant Did Not Want Others to Notice Participant Was Taking Medications</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Missing Study Pills Because Participant Had a Change in Daily Routine</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Missing Pills Because Participant Felt Like the Study Pill Was Toxic/Harmful</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Missing Study Pills Because Participant Fell Asleep/Slept Through Dose Time</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Missing Study Pills Because Participant Felt Sick or Ill</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Missing Study Pills Because Participant Felt Depressed/Overwhelmed</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Missing Study Pills Because Participant Ran Out of Study Pills</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Missing Study Pills Because Participant Didn't Think it Was Needed Because he/She Was Not Engaged in Risky Sex</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Thought They Were on Placebo vs. Pre-Exposure Prophylaxis (PrEP) at Week 4</measure>
    <time_frame>Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Thought They Were on Placebo vs. Pre-Exposure Prophylaxis (PrEP) at Week 8</measure>
    <time_frame>Week 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Thought They Were on Placebo vs. Pre-Exposure Prophylaxis (PrEP) at Week 12</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Thought They Were on Placebo vs. Pre-Exposure Prophylaxis (PrEP) at Week 16</measure>
    <time_frame>Week 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Thought They Were on Placebo vs. Pre-Exposure Prophylaxis (PrEP) at Week 20</measure>
    <time_frame>Week 20</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Thought They Were on Placebo vs. Pre-Exposure Prophylaxis (PrEP) at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived Risk of Becoming HIV Positive at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;Because I am in this PrEP study, I am less concerned about becoming HIV positive&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived Risk of Becoming HIV Positive at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;Because I am in this PrEP study, I am less concerned about becoming HIV positive&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived Risk of Becoming HIV Positive at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;Because I am in this PrEP study, I am less concerned about becoming HIV positive&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived Risk of Becoming HIV Positive at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;Because I am in this PrEP study, I am less concerned about becoming HIV positive&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived Risk of Becoming HIV Positive at Week 20</measure>
    <time_frame>Week 20</time_frame>
    <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;Because I am in this PrEP study, I am less concerned about becoming HIV positive&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived Risk of Becoming HIV Positive at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;Because I am in this PrEP study, I am less concerned about becoming HIV positive&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived HIV Risk Reduction at Week 4: Willingness to Take a Chance of Getting HIV Infected Because Participating in This PrEP Study</measure>
    <time_frame>Week 4</time_frame>
    <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;I am more willing to take a chance of getting infected now that I am in this PrEP study&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived HIV Risk Reduction at Week 8: Willingness to Take a Chance of Getting HIV Infected Because Participating in This PrEP Study</measure>
    <time_frame>Week 8</time_frame>
    <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;I am more willing to take a chance of getting infected now that I am in this PrEP study&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived HIV Risk Reduction at Week 12: Willingness to Take a Chance of Getting HIV Infected Because Participating in This PrEP Study</measure>
    <time_frame>Week 12</time_frame>
    <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;I am more willing to take a chance of getting infected now that I am in this PrEP study&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived HIV Risk Reduction at Week 16: Willingness to Take a Chance of Getting HIV Infected Because Participating in This PrEP Study</measure>
    <time_frame>Week 16</time_frame>
    <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;I am more willing to take a chance of getting infected now that I am in this PrEP study&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived HIV Risk Reduction at Week 20: Willingness to Take a Chance of Getting HIV Infected Because Participating in This PrEP Study</measure>
    <time_frame>Week 20</time_frame>
    <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;I am more willing to take a chance of getting infected now that I am in this PrEP study&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived HIV Risk Reduction at Week 24: Willingness to Take a Chance of Getting HIV Infected Because Participating in This PrEP Study</measure>
    <time_frame>Week 24</time_frame>
    <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;I am more willing to take a chance of getting infected now that I am in this PrEP study.&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived HIV Risk Reduction at Week 4: Less Worried About 'Slipping up' Now That PrEP May be Taken Prior to Unprotected Sex</measure>
    <time_frame>Week 4</time_frame>
    <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;I am a lot less worried about 'slipping up' now that PrEP may be taken prior to unprotected sex.&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived HIV Risk Reduction at Week 8: Less Worried About 'Slipping up' Now That PrEP May be Taken Prior to Unprotected Sex</measure>
    <time_frame>Week 8</time_frame>
    <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;I am a lot less worried about 'slipping up' now that PrEP may be taken prior to unprotected sex.&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived HIV Risk Reduction at Week 12: Less Worried About 'Slipping up' Now That PrEP May be Taken Prior to Unprotected Sex</measure>
    <time_frame>Week 12</time_frame>
    <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;I am a lot less worried about 'slipping up' now that PrEP may be taken prior to unprotected sex.&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived HIV Risk Reduction at Week 16: Less Worried About 'Slipping up' Now That PrEP May be Taken Prior to Unprotected Sex</measure>
    <time_frame>Week 16</time_frame>
    <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;I am a lot less worried about 'slipping up' now that PrEP may be taken prior to unprotected sex.&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived HIV Risk Reduction at Week 20: Less Worried About 'Slipping up' Now That PrEP May be Taken Prior to Unprotected Sex</measure>
    <time_frame>Week 20</time_frame>
    <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;I am a lot less worried about 'slipping up' now that PrEP may be taken prior to unprotected sex.&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived HIV Risk Reduction at Week 24: Less Worried About 'Slipping up' Now That PrEP May be Taken Prior to Unprotected Sex</measure>
    <time_frame>Week 24</time_frame>
    <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;I am a lot less worried about 'slipping up' now that PrEP may be taken prior to unprotected sex.&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived HIV Risk Reduction at Week 4: Less Worried About Having Unprotected Sex Due to the Availability of PrEP</measure>
    <time_frame>Week 4</time_frame>
    <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;The availability of PrEP makes me less worried about having unprotected sex.&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived HIV Risk Reduction at Week 8: Less Worried About Having Unprotected Sex Due to the Availability of PrEP</measure>
    <time_frame>Week 8</time_frame>
    <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;The availability of PrEP makes me less worried about having unprotected sex.&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived HIV Risk Reduction at Week 12: Less Worried About Having Unprotected Sex Due to the Availability of PrEP</measure>
    <time_frame>Week 12</time_frame>
    <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;The availability of PrEP makes me less worried about having unprotected sex.&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived HIV Risk Reduction at Week 16: Less Worried About Having Unprotected Sex Due to the Availability of PrEP</measure>
    <time_frame>Week 16</time_frame>
    <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;The availability of PrEP makes me less worried about having unprotected sex.&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived HIV Risk Reduction at Week 20: Less Worried About Having Unprotected Sex Due to the Availability of PrEP</measure>
    <time_frame>Week 20</time_frame>
    <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;The availability of PrEP makes me less worried about having unprotected sex.&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived HIV Risk Reduction at Week 24: Less Worried About Having Unprotected Sex Due to the Availability of PrEP</measure>
    <time_frame>Week 24</time_frame>
    <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;The availability of PrEP makes me less worried about having unprotected sex.&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived HIV Risk Reduction at Week 4: Less Concerned About Unprotected Anal Sex Because Participating in This PrEP Study</measure>
    <time_frame>Week 4</time_frame>
    <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;I am less concerned about having unprotected anal sex now that I am in this PrEP study.&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived HIV Risk Reduction at Week 8: Less Concerned About Unprotected Anal Sex Because Participating in This PrEP Study</measure>
    <time_frame>Week 8</time_frame>
    <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;I am less concerned about having unprotected anal sex now that I am in this PrEP study.&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived HIV Risk Reduction at Week 12: Less Concerned About Unprotected Anal Sex Because Participating in This PrEP Study</measure>
    <time_frame>Week 12</time_frame>
    <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;I am less concerned about having unprotected anal sex now that I am in this PrEP study.&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived HIV Risk Reduction at Week 16: Less Concerned About Unprotected Anal Sex Because Participating in This PrEP Study</measure>
    <time_frame>Week 16</time_frame>
    <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;I am less concerned about having unprotected anal sex now that I am in this PrEP study.&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived HIV Risk Reduction at Week 20: Less Concerned About Unprotected Anal Sex Because Participating in This PrEP Study</measure>
    <time_frame>Week 20</time_frame>
    <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;I am less concerned about having unprotected anal sex now that I am in this PrEP study.&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived HIV Risk Reduction at Week 24: Less Concerned About Unprotected Anal Sex Because Participating in This PrEP Study</measure>
    <time_frame>Week 24</time_frame>
    <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;I am less concerned about having unprotected anal sex now that I am in this PrEP study.&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived HIV Risk Reduction at Week 4: Participant Has Already Risked Getting HIV Infected Through Unprotected Sex While on This PrEP Study</measure>
    <time_frame>Week 4</time_frame>
    <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;I have already risked getting infected with HIV through unsafe sex while I've been in this study.&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived HIV Risk Reduction at Week 8: Participant Has Already Risked Getting HIV Infected Through Unprotected Sex While on This PrEP Study</measure>
    <time_frame>Week 8</time_frame>
    <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;I have already risked getting infected with HIV through unsafe sex while I've been in this study.&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived HIV Risk Reduction at Week 12: Participant Has Already Risked Getting HIV Infected Through Unprotected Sex While on This PrEP Study</measure>
    <time_frame>Week 12</time_frame>
    <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;I have already risked getting infected with HIV through unsafe sex while I've been on this study.&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived HIV Risk Reduction at Week 16: Participant Has Already Risked Getting HIV Infected Through Unprotected Sex While on This PrEP Study</measure>
    <time_frame>Week 16</time_frame>
    <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;I have already risked getting infected with HIV through unsafe sex while I've been in this study.&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived HIV Risk Reduction at Week 20: Participant Has Already Risked Getting HIV Infected Through Unprotected Sex While on This PrEP Study</measure>
    <time_frame>Week 20</time_frame>
    <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;I have already risked getting infected with HIV through unsafe sex while I've been in this study.&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived HIV Risk Reduction at Week 24: Participant Has Already Risked Getting HIV Infected Through Unprotected Sex While on This PrEP Study</measure>
    <time_frame>Week 24</time_frame>
    <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;I have already risked getting infected with HIV through unsafe sex while I've been in this study.&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting No High-Risk Man With Man Sex Acts at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>A high-risk sex act was defined as an answer of greater than 0 to any of the following questions:
With your male HIV positive male partners during the past month:
How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom? How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting No High-Risk Man With Man Sex Acts at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>A high-risk sex act was defined as an answer of greater than 0 to any of the following questions:
With your male HIV positive male partners during the past month:
How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom? How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting No High-Risk Man With Man Sex Acts at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>A high-risk sex act was defined as an answer of greater than 0 to any of the following questions:
With your male HIV positive male partners during the past month:
How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom? How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting No High-Risk Man With Man Sex Acts at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>A high-risk sex act was defined as an answer of greater than 0 to any of the following questions:
With your male HIV positive male partners during the past month:
How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom? How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting No High-Risk Man With Man Sex Acts at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>A high-risk sex act was defined as an answer of greater than 0 to any of the following questions:
With your male HIV positive male partners during the past month:
How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom? How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting No High-Risk Man With Man Sex Acts at Week 20</measure>
    <time_frame>Week 20</time_frame>
    <description>A high-risk sex act was defined as an answer of greater than 0 to any of the following questions:
With your male HIV positive male partners during the past month:
How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom? How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting No High-Risk Man With Man Sex Acts at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>A high-risk sex act was defined as an answer of greater than 0 to any of the following questions:
With your male HIV positive male partners during the past month:
How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom? How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom?</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>FTC/TDF as PrEP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Pill Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Blinded administration of placebo pill; HIV behavioral intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Pill Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects receive HIV behavioral intervention but no pill.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP</intervention_name>
    <description>Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.</description>
    <arm_group_label>FTC/TDF as PrEP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.</description>
    <arm_group_label>Placebo Pill Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Many Men, Many Voices (3MV)</intervention_name>
    <description>Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
    <arm_group_label>FTC/TDF as PrEP</arm_group_label>
    <arm_group_label>Placebo Pill Control</arm_group_label>
    <arm_group_label>No Pill Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to independently provide written informed consent;

          -  Of male gender at birth;

          -  Between the ages of 18 years and 0 days through 22 years and 364 days at the time of
             signed informed consent;

          -  Self-reporting at least one episode of unprotected anal intercourse with a male within
             the last 12 months at the time of Personal Digital Assistant (PDA) Screening
             Interview;

          -  Tests HIV negative at time of screening (using any FDA-approved HIV diagnostic test);

          -  Willing to provide locator information to study staff;

          -  Willing to be assigned to any of the three biomedical intervention conditions;

          -  Does not report intention to relocate out of the study area during the course of the
             study; and

          -  Does not have job/other obligations that would require long absences from the area (&gt;
             4 weeks at a time).

        Exclusion Criteria:

          -  Transgender (behavioral intervention not targeted toward this population);

          -  Presence of serious psychiatric symptoms (e.g., active hallucinations);

          -  Visibly distraught at the time of consent (e.g., suicidal, homicidal, exhibiting
             violent behavior);

          -  Intoxicated or under the influence of alcohol or other drugs at the time of consent;

          -  Acute or chronic hepatitis B infection (exclude if hepatitis B surface antigen
             positive);

          -  Renal dysfunction (Creatinine Clearance &lt; 75 ml/min); Use Cockcroft-Gault equation:
             Glomerular Filtration Rate (GFR) = (140-Age in years) x (Weight in kg) / (72 x serum
             creatinine) for males

          -  Any history of bone fractures not explained by trauma;

          -  Confirmed proteinuria (repeated positive [&gt; 2+] urine dipstick), unless explained by
             orthostatic proteinuria;

          -  Confirmed glucosuria (repeated positive [&gt; 1+] urine dipstick) in the presence of
             normal blood glucose (&lt;120 mg/dL);

          -  Any Grade 3 toxicity on screening tests/assessments;

          -  Concurrent participation in an HIV vaccine study or other investigational drug study;
             or

          -  Known allergy/sensitivity to the study drug or its components.

          -  Use of disallowed medications
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>22 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sybil Hosek, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Adolescent Trials Network</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ruth M Rothstein CORE Center/ John H Stroger Jr Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.atnonline.org</url>
    <description>Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Website</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2009</study_first_submitted>
  <study_first_submitted_qc>December 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2009</study_first_posted>
  <results_first_submitted>October 28, 2014</results_first_submitted>
  <results_first_submitted_qc>February 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 29, 2017</results_first_posted>
  <last_update_submitted>April 14, 2017</last_update_submitted>
  <last_update_submitted_qc>April 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pre-exposure prophylaxis</keyword>
  <keyword>HIV Prevention</keyword>
  <keyword>Truvada</keyword>
  <keyword>Many Men, Many Voices</keyword>
  <keyword>Emtricitabine</keyword>
  <keyword>Tenofovir disoproxil fumarate</keyword>
  <keyword>Young men who have sex with men</keyword>
  <keyword>HIV Seronegativity</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This research was conducted at two clinical sites in Chicago. Accrual was open between August 2009 and May 2011.</recruitment_details>
      <pre_assignment_details>Young males were approached for screening in the community. If eligible, a clinic-based screening was done to confirm eligibility. If confirmed, participants attended a behavioral intervention. Then a week 0 was scheduled for randomization. 68 participants were enrolled; 10 discontinued prior to randomization, for a total of 58 participants.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>FTC/TDF as PrEP</title>
          <description>Blinded treatment with FTC (Emtricitabine) and Tenofovir (TDf) Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Pill Control</title>
          <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
        </group>
        <group group_id="P3">
          <title>No Pill Control</title>
          <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Enrolled in Extension Study</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FTC/TDF as PrEP</title>
          <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Pill Control</title>
          <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
        </group>
        <group group_id="B3">
          <title>No Pill Control</title>
          <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="19"/>
            <count group_id="B4" value="58"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.8" spread="1.44"/>
                    <measurement group_id="B2" value="20.26" spread="1.45"/>
                    <measurement group_id="B3" value="19.84" spread="0.96"/>
                    <measurement group_id="B4" value="19.97" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education</title>
          <description>Not all participants answered every question.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Eighth Grade of Less</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GED</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Highschool Diploma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Some College</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current Employment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Unemployed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Housing Experience (Responded YES)</title>
          <description>Not all participants answered every question</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Kicked out of House Due to Sexual Orientation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spent at least 1 Night in Shelter S</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Have Exchanged Sex for Money or Place to Stay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Unprotected Anal Sex with Man in Past 30 Days</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Unprotected Anal or Vaginal Sex with Woman</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Actual Number of Study Visits Completed by 24 Weeks</title>
        <description>This outcome measure looked at whether the actual number of study visits conducted by 24 weeks differed by treatment group over time.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Actual Number of Study Visits Completed by 24 Weeks</title>
          <description>This outcome measure looked at whether the actual number of study visits conducted by 24 weeks differed by treatment group over time.</description>
          <units>Visits</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5927" spread="0.7387"/>
                    <measurement group_id="O2" value="4.6263" spread="0.9783"/>
                    <measurement group_id="O3" value="4.6374" spread="0.9784"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6983</p_value>
            <p_value_desc>The p-value is for the difference in treatment (TX) groups overall. The interaction between TX group and study time that tests whether the TX groups differed over time could not be tested due to small no. of subjects that missed visits during study.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting No High-Risk Man With Man Sex Acts at Baseline</title>
        <description>A high-risk sex act was defined as an answer of greater than 0 to any of the following questions:
With your male HIV positive male partners during the past month:
How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom? How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom?</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting No High-Risk Man With Man Sex Acts at Baseline</title>
          <description>A high-risk sex act was defined as an answer of greater than 0 to any of the following questions:
With your male HIV positive male partners during the past month:
How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom? How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom?</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8722</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Acceptability of Size of Pill</title>
        <time_frame>Week 24</time_frame>
        <population>Not all participants answered every question and therefore the number of responses in the outcome measure data table does not match the number of participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Acceptability of Size of Pill</title>
          <population>Not all participants answered every question and therefore the number of responses in the outcome measure data table does not match the number of participants analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Did not like it at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not like</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liked a lot</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6921</p_value>
            <p_value_desc>Not all subjects answered every question.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Acceptability of the Taste of the Pill</title>
        <time_frame>Week 24</time_frame>
        <population>Not all participants answered every question and therefore the number of responses in the outcome measure data table does not match the number of participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Acceptability of the Taste of the Pill</title>
          <population>Not all participants answered every question and therefore the number of responses in the outcome measure data table does not match the number of participants analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Did not like it at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not like</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liked a lot</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4655</p_value>
            <p_value_desc>Not all participants answered every question</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Acceptability of the Color of the Pill</title>
        <time_frame>Week 24</time_frame>
        <population>Not all participants answered every question and therefore the number of responses in the outcome measure data table does not match the number of participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Acceptability of the Color of the Pill</title>
          <population>Not all participants answered every question and therefore the number of responses in the outcome measure data table does not match the number of participants analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Did not like it at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not like</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liked a lot</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9999</p_value>
            <p_value_desc>Not all participants answered every question</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Acceptability of Taking the Pill Everyday</title>
        <time_frame>Week 24</time_frame>
        <population>Not all participants answered every question and therefore the number of responses in the outcome measure data table does not match the number of participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Acceptability of Taking the Pill Everyday</title>
          <population>Not all participants answered every question and therefore the number of responses in the outcome measure data table does not match the number of participants analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Did not like it at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not like</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liked a lot</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2297</p_value>
            <p_value_desc>Not all participants answered every question</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Acceptability of Taking Part in the Study</title>
        <time_frame>Week 24</time_frame>
        <population>Not all participants answered every question and therefore the number of responses in the outcome measure data table does not match the number of participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Acceptability of Taking Part in the Study</title>
          <population>Not all participants answered every question and therefore the number of responses in the outcome measure data table does not match the number of participants analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Did not like it at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not like</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liked a lot</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1886</p_value>
            <p_value_desc>Not all participants answered every question</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Acceptability of Participating in Group Sessions</title>
        <time_frame>Week 24</time_frame>
        <population>Not all participants answered every question and therefore the number of responses in the outcome measure data table does not match the number of participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Acceptability of Participating in Group Sessions</title>
          <population>Not all participants answered every question and therefore the number of responses in the outcome measure data table does not match the number of participants analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Did not like it at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not like</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liked a lot</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1908</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Acceptability of Being Randomly Assigned to a Group</title>
        <time_frame>Week 24</time_frame>
        <population>Not all participants answered every question and therefore the number of responses in the outcome measure data table does not match the number of participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Acceptability of Being Randomly Assigned to a Group</title>
          <population>Not all participants answered every question and therefore the number of responses in the outcome measure data table does not match the number of participants analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Did not like it at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not like</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liked a lot</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2240</p_value>
            <p_value_desc>Not all participants answered every question</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Acceptability of Having an HIV Test at Every Visit</title>
        <time_frame>Week 24</time_frame>
        <population>Not all participants answered every question and therefore the number of responses in the outcome measure data table does not match the number of participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Acceptability of Having an HIV Test at Every Visit</title>
          <population>Not all participants answered every question and therefore the number of responses in the outcome measure data table does not match the number of participants analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Did not like</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liked a lot</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1538</p_value>
            <p_value_desc>Not all participants answered every question</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Acceptability of Risk Reduction Counseling at Every Visit</title>
        <time_frame>Week 24</time_frame>
        <population>Not all participants answered every question and therefore the number of responses in the outcome measure data table does not match the number of participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Acceptability of Risk Reduction Counseling at Every Visit</title>
          <population>Not all participants answered every question and therefore the number of responses in the outcome measure data table does not match the number of participants analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Did not like it at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liked a lot</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2151</p_value>
            <p_value_desc>Not all participants answered every question</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Acceptability of Questions About Sexual Behavior at Every Visit</title>
        <time_frame>Week 24</time_frame>
        <population>Not all participants answered every question and therefore the number of responses in the outcome measure data table does not match the number of participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Acceptability of Questions About Sexual Behavior at Every Visit</title>
          <population>Not all participants answered every question and therefore the number of responses in the outcome measure data table does not match the number of participants analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Did not like it at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not like</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liked a lot</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2809</p_value>
            <p_value_desc>Not all participants answered every question</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Acceptability of Being Contacted by the Research Team in Between Visits</title>
        <time_frame>Week 24</time_frame>
        <population>Not all participants answered every question and therefore the number of responses in the outcome measure data table does not match the number of participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Acceptability of Being Contacted by the Research Team in Between Visits</title>
          <population>Not all participants answered every question and therefore the number of responses in the outcome measure data table does not match the number of participants analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Did not like</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liked a lot</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1850</p_value>
            <p_value_desc>Not all participants answered every question</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Acceptability of Physical Examination by a Doctor</title>
        <time_frame>Week 24</time_frame>
        <population>Not all participants answered every question and therefore the number of responses in the outcome measure data table does not match the number of participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Acceptability of Physical Examination by a Doctor</title>
          <population>Not all participants answered every question and therefore the number of responses in the outcome measure data table does not match the number of participants analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Did not like it at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not like</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liked a lot</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2366</p_value>
            <p_value_desc>Not all participants answered every question</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Acceptability of Health Clinic for Study Visits</title>
        <time_frame>Week 24</time_frame>
        <population>Not all participants answered every question.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Acceptability of Health Clinic for Study Visits</title>
          <population>Not all participants answered every question.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Did not like</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liked a lot</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4089</p_value>
            <p_value_desc>Not all subjects answered every question.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Missed Doses Based on Self-Report Calendar Data-Week 4</title>
        <description>Missed doses were calculated as the number of days between the date that subject came in for their current visit and the last date the subject was dispensed medication minus the total number of days the subject records having taken their medication in the last 31 days based on self-report calendar data. Since each subject is given a 30 day supply of medication at each visit, any days after 30 days are assumed to be missed medication days and are included in the total. Participants were taking only one dose per day and thus, the number of missed doses is the same as the number of missed medication days.</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Missed Doses Based on Self-Report Calendar Data-Week 4</title>
          <description>Missed doses were calculated as the number of days between the date that subject came in for their current visit and the last date the subject was dispensed medication minus the total number of days the subject records having taken their medication in the last 31 days based on self-report calendar data. Since each subject is given a 30 day supply of medication at each visit, any days after 30 days are assumed to be missed medication days and are included in the total. Participants were taking only one dose per day and thus, the number of missed doses is the same as the number of missed medication days.</description>
          <units>Missed Doses</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="0" upper_limit="32"/>
                    <measurement group_id="O2" value="10" lower_limit="0" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9999</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Missed Doses Based on Self-Report Calendar Data-Week 8</title>
        <description>Missed doses were calculated as the number of days between the date that subject came in for their current visit and the last date the subject was dispensed medication minus the total number of days the subject records having taken their medication in the last 31 days based on self-report calendar data. Since each subject is given a 30 day supply of medication at each visit, any days after 30 days are assumed to be missed medication days and are included in the total. Participants were taking only one dose per day and thus, the number of missed doses is the same as the number of missed medication days.</description>
        <time_frame>Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Missed Doses Based on Self-Report Calendar Data-Week 8</title>
          <description>Missed doses were calculated as the number of days between the date that subject came in for their current visit and the last date the subject was dispensed medication minus the total number of days the subject records having taken their medication in the last 31 days based on self-report calendar data. Since each subject is given a 30 day supply of medication at each visit, any days after 30 days are assumed to be missed medication days and are included in the total. Participants were taking only one dose per day and thus, the number of missed doses is the same as the number of missed medication days.</description>
          <units>Missed Doses</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="0" upper_limit="28"/>
                    <measurement group_id="O2" value="8" lower_limit="0" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9999</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Missed Doses Based on Self-Report Calendar Data-Week 12</title>
        <description>Missed doses were calculated as the number of days between the date that subject came in for their current visit and the last date the subject was dispensed medication minus the total number of days the subject records having taken their medication in the last 31 days based on self-report calendar data. Since each subject is given a 30 day supply of medication at each visit, any days after 30 days are assumed to be missed medication days and are included in the total. Participants were taking only one dose per day and thus, the number of missed doses is the same as the number of missed medication days.</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Missed Doses Based on Self-Report Calendar Data-Week 12</title>
          <description>Missed doses were calculated as the number of days between the date that subject came in for their current visit and the last date the subject was dispensed medication minus the total number of days the subject records having taken their medication in the last 31 days based on self-report calendar data. Since each subject is given a 30 day supply of medication at each visit, any days after 30 days are assumed to be missed medication days and are included in the total. Participants were taking only one dose per day and thus, the number of missed doses is the same as the number of missed medication days.</description>
          <units>Missed Doses</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="0" upper_limit="29"/>
                    <measurement group_id="O2" value="6.5" lower_limit="0" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9999</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Missed Doses Based on Self-Report Calendar Data-Week 16</title>
        <description>Missed doses were calculated as the number of days between the date that subject came in for their current visit and the last date the subject was dispensed medication minus the total number of days the subject records having taken their medication in the last 31 days based on self-report calendar data. Since each subject is given a 30 day supply of medication at each visit, any days after 30 days are assumed to be missed medication days and are included in the total. Participants were taking only one dose per day and thus, the number of missed doses is the same as the number of missed medication days.</description>
        <time_frame>Week 16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Missed Doses Based on Self-Report Calendar Data-Week 16</title>
          <description>Missed doses were calculated as the number of days between the date that subject came in for their current visit and the last date the subject was dispensed medication minus the total number of days the subject records having taken their medication in the last 31 days based on self-report calendar data. Since each subject is given a 30 day supply of medication at each visit, any days after 30 days are assumed to be missed medication days and are included in the total. Participants were taking only one dose per day and thus, the number of missed doses is the same as the number of missed medication days.</description>
          <units>Missed Doses</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="0" upper_limit="27"/>
                    <measurement group_id="O2" value="19" lower_limit="0" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7007</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Missed Doses Based on Self-Report Calendar Data-Week 20</title>
        <description>Missed doses were calculated as the number of days between the date that subject came in for their current visit and the last date the subject was dispensed medication minus the total number of days the subject records having taken their medication in the last 31 days based on self-report calendar data. Since each subject is given a 30 day supply of medication at each visit, any days after 30 days are assumed to be missed medication days and are included in the total. Participants were taking only one dose per day and thus, the number of missed doses is the same as the number of missed medication days.</description>
        <time_frame>Week 20</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Missed Doses Based on Self-Report Calendar Data-Week 20</title>
          <description>Missed doses were calculated as the number of days between the date that subject came in for their current visit and the last date the subject was dispensed medication minus the total number of days the subject records having taken their medication in the last 31 days based on self-report calendar data. Since each subject is given a 30 day supply of medication at each visit, any days after 30 days are assumed to be missed medication days and are included in the total. Participants were taking only one dose per day and thus, the number of missed doses is the same as the number of missed medication days.</description>
          <units>Missed Doses</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="0" upper_limit="35"/>
                    <measurement group_id="O2" value="10" lower_limit="0" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9999</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Missed Doses Based on Self-Report Calendar Data-Week 24</title>
        <description>Missed doses were calculated as the number of days between the date that subject came in for their current visit and the last date the subject was dispensed medication minus the total number of days the subject records having taken their medication in the last 31 days based on self-report calendar data. Since each subject is given a 30 day supply of medication at each visit, any days after 30 days are assumed to be missed medication days and are included in the total. Participants were taking only one dose per day and thus, the number of missed doses is the same as the number of missed medication days.</description>
        <time_frame>Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Missed Doses Based on Self-Report Calendar Data-Week 24</title>
          <description>Missed doses were calculated as the number of days between the date that subject came in for their current visit and the last date the subject was dispensed medication minus the total number of days the subject records having taken their medication in the last 31 days based on self-report calendar data. Since each subject is given a 30 day supply of medication at each visit, any days after 30 days are assumed to be missed medication days and are included in the total. Participants were taking only one dose per day and thus, the number of missed doses is the same as the number of missed medication days.</description>
          <units>Missed Doses</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="0" upper_limit="35"/>
                    <measurement group_id="O2" value="5.5" lower_limit="0" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9999</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Missed Doses Over Time Based on Self-Report Calendar Data</title>
        <description>The outcome measure presents the least square means from the generalized linear model. The outcome here is a binary variable that determines whether the subject missed a dose or not. In a binomial model with logit link, the least squares means are predicted population margins of the logits.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Missed Doses Over Time Based on Self-Report Calendar Data</title>
          <description>The outcome measure presents the least square means from the generalized linear model. The outcome here is a binary variable that determines whether the subject missed a dose or not. In a binomial model with logit link, the least squares means are predicted population margins of the logits.</description>
          <units>Doses</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4752" spread="0.3965"/>
                    <measurement group_id="O2" value="0.4021" spread="0.3596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8934</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Missed Doses Based on Medication Refill Dates-Week 4</title>
        <description>Missed doses were calculated as the number of days between the actual and expected refill dates. Participants were taking only one dose per day and thus, the number of missed doses is the same as the number of missed medication days.</description>
        <time_frame>Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Missed Doses Based on Medication Refill Dates-Week 4</title>
          <description>Missed doses were calculated as the number of days between the actual and expected refill dates. Participants were taking only one dose per day and thus, the number of missed doses is the same as the number of missed medication days.</description>
          <units>Missed doses</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="7"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9999</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Missed Doses Based on Medication Refill Dates-Week 8</title>
        <description>Missed doses were calculated as the number of days between the actual and expected refill dates. Participants were taking only one dose per day and thus, the number of missed doses is the same as the number of missed medication days.</description>
        <time_frame>Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Missed Doses Based on Medication Refill Dates-Week 8</title>
          <description>Missed doses were calculated as the number of days between the actual and expected refill dates. Participants were taking only one dose per day and thus, the number of missed doses is the same as the number of missed medication days.</description>
          <units>Missed doses</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9999</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Missed Doses Based on Medication Refill Dates-Week 12</title>
        <description>Missed doses were calculated as the number of days between the actual and expected refill dates. Participants were taking only one dose per day and thus, the number of missed doses is the same as the number of missed medication days.</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Missed Doses Based on Medication Refill Dates-Week 12</title>
          <description>Missed doses were calculated as the number of days between the actual and expected refill dates. Participants were taking only one dose per day and thus, the number of missed doses is the same as the number of missed medication days.</description>
          <units>Missed doses</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="7"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9999</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Missed Doses Based on Medication Refill Dates-Week 16</title>
        <description>Missed doses were calculated as the number of days between the actual and expected refill dates. Participants were taking only one dose per day and thus, the number of missed doses is the same as the number of missed medication days.</description>
        <time_frame>Week 16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Missed Doses Based on Medication Refill Dates-Week 16</title>
          <description>Missed doses were calculated as the number of days between the actual and expected refill dates. Participants were taking only one dose per day and thus, the number of missed doses is the same as the number of missed medication days.</description>
          <units>Missed doses</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="8"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4003</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Missed Doses Based on Medication Refill Dates-Week 20</title>
        <description>Missed doses were calculated as the number of days between the actual and expected refill dates. Participants were taking only one dose per day and thus, the number of missed doses is the same as the number of missed medication days.</description>
        <time_frame>Week 20</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Missed Doses Based on Medication Refill Dates-Week 20</title>
          <description>Missed doses were calculated as the number of days between the actual and expected refill dates. Participants were taking only one dose per day and thus, the number of missed doses is the same as the number of missed medication days.</description>
          <units>Missed doses</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6462</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Missed Doses Based on Medication Refill Dates-Overall</title>
        <description>Missed doses were calculated as the number of days between the actual and expected refill dates. Participants were taking only one dose per day and thus, the number of missed doses is the same as the number of missed medication days.</description>
        <time_frame>20 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Missed Doses Based on Medication Refill Dates-Overall</title>
          <description>Missed doses were calculated as the number of days between the actual and expected refill dates. Participants were taking only one dose per day and thus, the number of missed doses is the same as the number of missed medication days.</description>
          <units>Missed doses</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="8"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8505</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Tenofovir Plasma Concentrations (mg/mL) Detected at Baseline</title>
        <description>Subjects reporting tenofovir is calculated as those subjects that had a tenofovir plasma concentration greater than zero (BLQ). Subjects with BLQ+ (&lt;10 ng/mL) were included in this count.</description>
        <time_frame>Baseline</time_frame>
        <population>Only two subjects in the Placebo Pill Control arm were randomly selected for tenofovir plasma concentration testing at baseline. All subjects in the FTC/TDF as PrEP arm had tenofovir plasma concentration testing and no subjects in the No Pill arm had tenofovir plasma concentration testing at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Tenofovir Plasma Concentrations (mg/mL) Detected at Baseline</title>
          <description>Subjects reporting tenofovir is calculated as those subjects that had a tenofovir plasma concentration greater than zero (BLQ). Subjects with BLQ+ (&lt;10 ng/mL) were included in this count.</description>
          <population>Only two subjects in the Placebo Pill Control arm were randomly selected for tenofovir plasma concentration testing at baseline. All subjects in the FTC/TDF as PrEP arm had tenofovir plasma concentration testing and no subjects in the No Pill arm had tenofovir plasma concentration testing at baseline.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Tenofovir Plasma Concentrations (mg/mL) Detected at Week 4</title>
        <description>Subjects reporting tenofovir is calculated as those subjects that had a tenofovir plasma concentration greater than zero (BLQ). Subjects with BLQ+ (&lt;10 ng/mL) were included in this count.</description>
        <time_frame>Week 4</time_frame>
        <population>Only two subjects in the Placebo Pill Control arm were randomly selected for tenofovir plasma concentration testing at Week 4. 19 subjects in the FTC/TDF as PrEP arm had tenofovir plasma concentration testing and no subjects in the No Pill arm had tenofovir plasma concentration testing at Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Tenofovir Plasma Concentrations (mg/mL) Detected at Week 4</title>
          <description>Subjects reporting tenofovir is calculated as those subjects that had a tenofovir plasma concentration greater than zero (BLQ). Subjects with BLQ+ (&lt;10 ng/mL) were included in this count.</description>
          <population>Only two subjects in the Placebo Pill Control arm were randomly selected for tenofovir plasma concentration testing at Week 4. 19 subjects in the FTC/TDF as PrEP arm had tenofovir plasma concentration testing and no subjects in the No Pill arm had tenofovir plasma concentration testing at Week 4.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Tenofovir Plasma Concentrations (mg/mL) Detected at Week 8</title>
        <description>Subjects reporting tenofovir is calculated as those subjects that had a tenofovir plasma concentration greater than zero (BLQ). Subjects with BLQ+ (&lt;10 ng/mL) were included in this count.</description>
        <time_frame>Week 8</time_frame>
        <population>18 subjects in the Placebo Pill Control arm were randomly selected for tenofovir plasma concentration testing at Week 8. 17 subjects in the FTC/TDF as PrEP arm had tenofovir plasma concentration testing and 17 subjects in the No Pill arm had tenofovir plasma concentration testing at Week 8.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Tenofovir Plasma Concentrations (mg/mL) Detected at Week 8</title>
          <description>Subjects reporting tenofovir is calculated as those subjects that had a tenofovir plasma concentration greater than zero (BLQ). Subjects with BLQ+ (&lt;10 ng/mL) were included in this count.</description>
          <population>18 subjects in the Placebo Pill Control arm were randomly selected for tenofovir plasma concentration testing at Week 8. 17 subjects in the FTC/TDF as PrEP arm had tenofovir plasma concentration testing and 17 subjects in the No Pill arm had tenofovir plasma concentration testing at Week 8.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Tenofovir Plasma Concentrations (mg/mL) Detected at Week 12</title>
        <description>Subjects reporting tenofovir is calculated as those subjects that had a tenofovir plasma concentration greater than zero (BLQ). Subjects with BLQ+ (&lt;10 ng/mL) were included in this count.</description>
        <time_frame>Week 12</time_frame>
        <population>One subject in the Placebo Pill Control arm was randomly selected for tenofovir plasma concentration testing at Week 12. 15 subjects in the FTC/TDF as PrEP arm had tenofovir plasma concentration testing and 1 subject in the No Pill arm had tenofovir plasma concentration testing at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Tenofovir Plasma Concentrations (mg/mL) Detected at Week 12</title>
          <description>Subjects reporting tenofovir is calculated as those subjects that had a tenofovir plasma concentration greater than zero (BLQ). Subjects with BLQ+ (&lt;10 ng/mL) were included in this count.</description>
          <population>One subject in the Placebo Pill Control arm was randomly selected for tenofovir plasma concentration testing at Week 12. 15 subjects in the FTC/TDF as PrEP arm had tenofovir plasma concentration testing and 1 subject in the No Pill arm had tenofovir plasma concentration testing at Week 12.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Tenofovir Plasma Concentrations (mg/mL) Detected at Week 16</title>
        <description>Subjects reporting tenofovir is calculated as those subjects that had a tenofovir plasma concentration greater than zero (BLQ). Subjects with BLQ+ (&lt;10 ng/mL) were included in this count.</description>
        <time_frame>Week 16</time_frame>
        <population>13 subjects in the Placebo Pill Control arm were randomly selected for tenofovir plasma concentration testing at Week 16. 13 subjects in the FTC/TDF as PrEP arm had tenofovir plasma concentration testing and 14 subjects in the No Pill arm had tenofovir plasma concentration testing at Week 16.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Tenofovir Plasma Concentrations (mg/mL) Detected at Week 16</title>
          <description>Subjects reporting tenofovir is calculated as those subjects that had a tenofovir plasma concentration greater than zero (BLQ). Subjects with BLQ+ (&lt;10 ng/mL) were included in this count.</description>
          <population>13 subjects in the Placebo Pill Control arm were randomly selected for tenofovir plasma concentration testing at Week 16. 13 subjects in the FTC/TDF as PrEP arm had tenofovir plasma concentration testing and 14 subjects in the No Pill arm had tenofovir plasma concentration testing at Week 16.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.8"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Tenofovir Plasma Concentrations (mg/mL) Detected at Week 20</title>
        <description>Subjects reporting tenofovir is calculated as those subjects that had a tenofovir plasma concentration greater than zero (BLQ). Subjects with BLQ+ (&lt;10 ng/mL) were included in this count.</description>
        <time_frame>Week 20</time_frame>
        <population>One subject in the Placebo Pill Control arm was randomly selected for tenofovir plasma concentration testing at Week 20. 12 subjects in the FTC/TDF as PrEP arm had tenofovir plasma concentration testing and no subjects in the No Pill arm had tenofovir plasma concentration testing at Week 20.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Tenofovir Plasma Concentrations (mg/mL) Detected at Week 20</title>
          <description>Subjects reporting tenofovir is calculated as those subjects that had a tenofovir plasma concentration greater than zero (BLQ). Subjects with BLQ+ (&lt;10 ng/mL) were included in this count.</description>
          <population>One subject in the Placebo Pill Control arm was randomly selected for tenofovir plasma concentration testing at Week 20. 12 subjects in the FTC/TDF as PrEP arm had tenofovir plasma concentration testing and no subjects in the No Pill arm had tenofovir plasma concentration testing at Week 20.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Tenofovir Plasma Concentrations (mg/mL) Detected at Week 24</title>
        <description>Subjects reporting tenofovir is calculated as those subjects that had a tenofovir plasma concentration greater than zero (BLQ). Subjects with BLQ+ (&lt;10 ng/mL) were included in this count.</description>
        <time_frame>Week 24</time_frame>
        <population>No subjects in the Placebo Pill Control arm were randomly selected for tenofovir plasma concentration testing at Week 24. 10 subjects in the FTC/TDF as PrEP arm had tenofovir plasma concentration testing and no subjects in the No Pill arm had tenofovir plasma concentration testing at Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Tenofovir Plasma Concentrations (mg/mL) Detected at Week 24</title>
          <description>Subjects reporting tenofovir is calculated as those subjects that had a tenofovir plasma concentration greater than zero (BLQ). Subjects with BLQ+ (&lt;10 ng/mL) were included in this count.</description>
          <population>No subjects in the Placebo Pill Control arm were randomly selected for tenofovir plasma concentration testing at Week 24. 10 subjects in the FTC/TDF as PrEP arm had tenofovir plasma concentration testing and no subjects in the No Pill arm had tenofovir plasma concentration testing at Week 24.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Missing Study Pills Because Participant Was Away From Home</title>
        <time_frame>24 Weeks</time_frame>
        <population>Participants in the No Pill Control arm were not included in the analysis. Analysis measure type is the percentage of participants in each frequency category for missed dose reason.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Missing Study Pills Because Participant Was Away From Home</title>
          <population>Participants in the No Pill Control arm were not included in the analysis. Analysis measure type is the percentage of participants in each frequency category for missed dose reason.</population>
          <units>% of participants in each category</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.76"/>
                    <measurement group_id="O2" value="48.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rarely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.12"/>
                    <measurement group_id="O2" value="20.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sometimes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.47"/>
                    <measurement group_id="O2" value="26.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Often</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.65"/>
                    <measurement group_id="O2" value="4.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7434</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Missing Study Pills Because Participant Was Too Busy With Other Things</title>
        <time_frame>24 Weeks</time_frame>
        <population>Participants in the No Pill Control arm were not included in the analysis. Analysis measure type is the percentage of participants in each frequency category for missed dose reason.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Missing Study Pills Because Participant Was Too Busy With Other Things</title>
          <population>Participants in the No Pill Control arm were not included in the analysis. Analysis measure type is the percentage of participants in each frequency category for missed dose reason.</population>
          <units>% of participants in each category</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.06"/>
                    <measurement group_id="O2" value="58.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rarely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.59"/>
                    <measurement group_id="O2" value="16.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sometimes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.29"/>
                    <measurement group_id="O2" value="21.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Often</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.06"/>
                    <measurement group_id="O2" value="4.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6153</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Missing Study Pills Because Participant Simply Forgot</title>
        <time_frame>24 Weeks</time_frame>
        <population>Participants in the No Pill Control arm were not included in the analysis. Analysis measure type is the percentage of participants in each frequency category for missed dose reason.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Missing Study Pills Because Participant Simply Forgot</title>
          <population>Participants in the No Pill Control arm were not included in the analysis. Analysis measure type is the percentage of participants in each frequency category for missed dose reason.</population>
          <units>% of participants in each category</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.82"/>
                    <measurement group_id="O2" value="60.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rarely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.00"/>
                    <measurement group_id="O2" value="16.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sometimes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.41"/>
                    <measurement group_id="O2" value="15.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Often</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.76"/>
                    <measurement group_id="O2" value="8.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2000</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Missing Study Pills Because Participant Had Too Many Study Pills to Take</title>
        <time_frame>24 weeks</time_frame>
        <population>Participants in the No Pill Control arm were not included in the analysis. Analysis measure type is the percentage of participants in each frequency category for missed dose reason.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Missing Study Pills Because Participant Had Too Many Study Pills to Take</title>
          <population>Participants in the No Pill Control arm were not included in the analysis. Analysis measure type is the percentage of participants in each frequency category for missed dose reason.</population>
          <units>% of participants in each category</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.94"/>
                    <measurement group_id="O2" value="95.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rarely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.06"/>
                    <measurement group_id="O2" value="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sometimes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Often</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5265</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Missing Study Pills Because Participant Wanted to Avoid Side Effects</title>
        <time_frame>24 weeks</time_frame>
        <population>Participants in the No Pill Control arm were not included in the analysis. Analysis measure type is the percentage of participants in each frequency category for missed dose reason.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Missing Study Pills Because Participant Wanted to Avoid Side Effects</title>
          <population>Participants in the No Pill Control arm were not included in the analysis. Analysis measure type is the percentage of participants in each frequency category for missed dose reason.</population>
          <units>% of participants in each category</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.35"/>
                    <measurement group_id="O2" value="91.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rarely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.41"/>
                    <measurement group_id="O2" value="3.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sometimes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Often</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.24"/>
                    <measurement group_id="O2" value="3.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2559</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Missing Study Pills Because Participant Did Not Want Others to Notice Participant Was Taking Medications</title>
        <time_frame>24 weeks</time_frame>
        <population>Participants in the No Pill Control arm were not included in the analysis. Analysis measure type is the percentage of participants in each frequency category for missed dose reason.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Missing Study Pills Because Participant Did Not Want Others to Notice Participant Was Taking Medications</title>
          <population>Participants in the No Pill Control arm were not included in the analysis. Analysis measure type is the percentage of participants in each frequency category for missed dose reason.</population>
          <units>% of participants in each category</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.24"/>
                    <measurement group_id="O2" value="92.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rarely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.88"/>
                    <measurement group_id="O2" value="4.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sometimes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35"/>
                    <measurement group_id="O2" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Often</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.53"/>
                    <measurement group_id="O2" value="3.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3846</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Missing Study Pills Because Participant Had a Change in Daily Routine</title>
        <time_frame>24 weeks</time_frame>
        <population>Participants in the No Pill Control arm were not included in the analysis. Analysis measure type is the percentage of participants in each frequency category for missed dose reason.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Missing Study Pills Because Participant Had a Change in Daily Routine</title>
          <population>Participants in the No Pill Control arm were not included in the analysis. Analysis measure type is the percentage of participants in each frequency category for missed dose reason.</population>
          <units>% of participants in each category</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.35"/>
                    <measurement group_id="O2" value="70.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rarely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.53"/>
                    <measurement group_id="O2" value="15.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sometimes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.06"/>
                    <measurement group_id="O2" value="10.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Often</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.06"/>
                    <measurement group_id="O2" value="3.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5133</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Missing Pills Because Participant Felt Like the Study Pill Was Toxic/Harmful</title>
        <time_frame>24 weeks</time_frame>
        <population>Participants in the No Pill Control arm were not included in the analysis. Analysis measure type is the percentage of participants in each frequency category for missed dose reason.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Missing Pills Because Participant Felt Like the Study Pill Was Toxic/Harmful</title>
          <population>Participants in the No Pill Control arm were not included in the analysis. Analysis measure type is the percentage of participants in each frequency category for missed dose reason.</population>
          <units>% of participants in each category</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.06"/>
                    <measurement group_id="O2" value="95.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rarely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.88"/>
                    <measurement group_id="O2" value="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sometimes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.53"/>
                    <measurement group_id="O2" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Often</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.53"/>
                    <measurement group_id="O2" value="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1661</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Missing Study Pills Because Participant Fell Asleep/Slept Through Dose Time</title>
        <time_frame>24 weeks</time_frame>
        <population>Participants in the No Pill Control arm were not included in the analysis. Analysis measure type is the percentage of participants in each frequency category for missed dose reason.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Missing Study Pills Because Participant Fell Asleep/Slept Through Dose Time</title>
          <population>Participants in the No Pill Control arm were not included in the analysis. Analysis measure type is the percentage of participants in each frequency category for missed dose reason.</population>
          <units>% of participants in each category</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.24"/>
                    <measurement group_id="O2" value="86.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rarely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.71"/>
                    <measurement group_id="O2" value="6.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sometimes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.71"/>
                    <measurement group_id="O2" value="4.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Often</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35"/>
                    <measurement group_id="O2" value="3.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0729</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Missing Study Pills Because Participant Felt Sick or Ill</title>
        <time_frame>24 weeks</time_frame>
        <population>Participants in the No Pill Control arm were not included in the analysis. Analysis measure type is the percentage of participants in each frequency category for missed dose reason.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Missing Study Pills Because Participant Felt Sick or Ill</title>
          <population>Participants in the No Pill Control arm were not included in the analysis. Analysis measure type is the percentage of participants in each frequency category for missed dose reason.</population>
          <units>% of participants in each category</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.18"/>
                    <measurement group_id="O2" value="89.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rarely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.76"/>
                    <measurement group_id="O2" value="5.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sometimes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.71"/>
                    <measurement group_id="O2" value="3.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Often</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35"/>
                    <measurement group_id="O2" value="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1912</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Missing Study Pills Because Participant Felt Depressed/Overwhelmed</title>
        <time_frame>24 weeks</time_frame>
        <population>Participants in the No Pill Control arm were not included in the analysis. Analysis measure type is the percentage of participants in each frequency category for missed dose reason.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Missing Study Pills Because Participant Felt Depressed/Overwhelmed</title>
          <population>Participants in the No Pill Control arm were not included in the analysis. Analysis measure type is the percentage of participants in each frequency category for missed dose reason.</population>
          <units>% of participants in each category</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.53"/>
                    <measurement group_id="O2" value="92.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rarely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.94"/>
                    <measurement group_id="O2" value="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sometimes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="3.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Often</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.53"/>
                    <measurement group_id="O2" value="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2829</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Missing Study Pills Because Participant Ran Out of Study Pills</title>
        <time_frame>24 weeks</time_frame>
        <population>Participants in the No Pill Control arm were not included in the analysis. Analysis measure type is the percentage of participants in each frequency category for missed dose reason.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Missing Study Pills Because Participant Ran Out of Study Pills</title>
          <population>Participants in the No Pill Control arm were not included in the analysis. Analysis measure type is the percentage of participants in each frequency category for missed dose reason.</population>
          <units>% of participants in each category</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.12"/>
                    <measurement group_id="O2" value="97.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rarely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.71"/>
                    <measurement group_id="O2" value="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sometimes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Often</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18"/>
                    <measurement group_id="O2" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2685</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Missing Study Pills Because Participant Didn't Think it Was Needed Because he/She Was Not Engaged in Risky Sex</title>
        <time_frame>24 weeks</time_frame>
        <population>Participants in the No Pill Control arm were not included in the analysis. Analysis measure type is the percentage of participants in each frequency category for missed dose reason.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Missing Study Pills Because Participant Didn't Think it Was Needed Because he/She Was Not Engaged in Risky Sex</title>
          <population>Participants in the No Pill Control arm were not included in the analysis. Analysis measure type is the percentage of participants in each frequency category for missed dose reason.</population>
          <units>% of participants in each category</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.59"/>
                    <measurement group_id="O2" value="96.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rarely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.71"/>
                    <measurement group_id="O2" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sometimes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18"/>
                    <measurement group_id="O2" value="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Often</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.53"/>
                    <measurement group_id="O2" value="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2342</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Thought They Were on Placebo vs. Pre-Exposure Prophylaxis (PrEP) at Week 4</title>
        <time_frame>Week 4</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Thought They Were on Placebo vs. Pre-Exposure Prophylaxis (PrEP) at Week 4</title>
          <population>Not all participants answered every question</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PrEP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Don't Know</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Don't Understand Question</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7314</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Thought They Were on Placebo vs. Pre-Exposure Prophylaxis (PrEP) at Week 8</title>
        <time_frame>Week 8</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Thought They Were on Placebo vs. Pre-Exposure Prophylaxis (PrEP) at Week 8</title>
          <population>Not all participants answered every question</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PrEP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Don't Know</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Don't Understand Question</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3770</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Thought They Were on Placebo vs. Pre-Exposure Prophylaxis (PrEP) at Week 12</title>
        <time_frame>Week 12</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Thought They Were on Placebo vs. Pre-Exposure Prophylaxis (PrEP) at Week 12</title>
          <population>Not all participants answered every question</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PrEP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Don't Know</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Don't Understand Question</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7004</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Thought They Were on Placebo vs. Pre-Exposure Prophylaxis (PrEP) at Week 16</title>
        <time_frame>Week 16</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Thought They Were on Placebo vs. Pre-Exposure Prophylaxis (PrEP) at Week 16</title>
          <population>Not all participants answered every question</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PrEP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Don't Know</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Don't Understand Question</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4668</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Thought They Were on Placebo vs. Pre-Exposure Prophylaxis (PrEP) at Week 20</title>
        <time_frame>Week 20</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Thought They Were on Placebo vs. Pre-Exposure Prophylaxis (PrEP) at Week 20</title>
          <population>Not all participants answered every question</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PrEP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Don't Know</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Don't Understand Question</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7573</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Thought They Were on Placebo vs. Pre-Exposure Prophylaxis (PrEP) at Week 24</title>
        <time_frame>Week 24</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Thought They Were on Placebo vs. Pre-Exposure Prophylaxis (PrEP) at Week 24</title>
          <population>Not all participants answered every question</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PrEP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Don't Know</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Don't Understand Question</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0356</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perceived Risk of Becoming HIV Positive at Week 4</title>
        <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;Because I am in this PrEP study, I am less concerned about becoming HIV positive&quot;.</description>
        <time_frame>Week 4</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived Risk of Becoming HIV Positive at Week 4</title>
          <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;Because I am in this PrEP study, I am less concerned about becoming HIV positive&quot;.</description>
          <population>Not all participants answered every question</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.63"/>
                    <measurement group_id="O2" value="38.89"/>
                    <measurement group_id="O3" value="33.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.05"/>
                    <measurement group_id="O2" value="33.33"/>
                    <measurement group_id="O3" value="22.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.53"/>
                    <measurement group_id="O2" value="11.11"/>
                    <measurement group_id="O3" value="27.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.79"/>
                    <measurement group_id="O2" value="11.11"/>
                    <measurement group_id="O3" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="5.56"/>
                    <measurement group_id="O3" value="16.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3176</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perceived Risk of Becoming HIV Positive at Week 8</title>
        <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;Because I am in this PrEP study, I am less concerned about becoming HIV positive&quot;.</description>
        <time_frame>Week 8</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived Risk of Becoming HIV Positive at Week 8</title>
          <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;Because I am in this PrEP study, I am less concerned about becoming HIV positive&quot;.</description>
          <population>Not all participants answered every question</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.41"/>
                    <measurement group_id="O2" value="66.67"/>
                    <measurement group_id="O3" value="58.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.65"/>
                    <measurement group_id="O2" value="27.78"/>
                    <measurement group_id="O3" value="11.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.53"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="11.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.53"/>
                    <measurement group_id="O2" value="5.56"/>
                    <measurement group_id="O3" value="11.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.88"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="5.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1348</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perceived Risk of Becoming HIV Positive at Week 12</title>
        <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;Because I am in this PrEP study, I am less concerned about becoming HIV positive&quot;.</description>
        <time_frame>Week 12</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived Risk of Becoming HIV Positive at Week 12</title>
          <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;Because I am in this PrEP study, I am less concerned about becoming HIV positive&quot;.</description>
          <population>Not all participants answered every question</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.00"/>
                    <measurement group_id="O2" value="75.00"/>
                    <measurement group_id="O3" value="31.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.00"/>
                    <measurement group_id="O2" value="6.25"/>
                    <measurement group_id="O3" value="37.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.00"/>
                    <measurement group_id="O2" value="6.25"/>
                    <measurement group_id="O3" value="12.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="12.50"/>
                    <measurement group_id="O3" value="6.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="12.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0420</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perceived Risk of Becoming HIV Positive at Week 16</title>
        <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;Because I am in this PrEP study, I am less concerned about becoming HIV positive&quot;.</description>
        <time_frame>Week 16</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived Risk of Becoming HIV Positive at Week 16</title>
          <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;Because I am in this PrEP study, I am less concerned about becoming HIV positive&quot;.</description>
          <population>Not all participants answered every question</population>
          <units>percentage of partcipants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.33"/>
                    <measurement group_id="O2" value="80.00"/>
                    <measurement group_id="O3" value="42.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.67"/>
                    <measurement group_id="O2" value="13.33"/>
                    <measurement group_id="O3" value="21.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.33"/>
                    <measurement group_id="O2" value="6.67"/>
                    <measurement group_id="O3" value="21.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.33"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.33"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="14.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4906</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perceived Risk of Becoming HIV Positive at Week 20</title>
        <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;Because I am in this PrEP study, I am less concerned about becoming HIV positive&quot;.</description>
        <time_frame>Week 20</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived Risk of Becoming HIV Positive at Week 20</title>
          <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;Because I am in this PrEP study, I am less concerned about becoming HIV positive&quot;.</description>
          <population>Not all participants answered every question</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.67"/>
                    <measurement group_id="O2" value="78.57"/>
                    <measurement group_id="O3" value="30.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.67"/>
                    <measurement group_id="O2" value="21.43"/>
                    <measurement group_id="O3" value="23.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="23.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.67"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="7.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="15.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0544</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perceived Risk of Becoming HIV Positive at Week 24</title>
        <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;Because I am in this PrEP study, I am less concerned about becoming HIV positive&quot;.</description>
        <time_frame>Week 24</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived Risk of Becoming HIV Positive at Week 24</title>
          <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;Because I am in this PrEP study, I am less concerned about becoming HIV positive&quot;.</description>
          <population>Not all participants answered every question</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.00"/>
                    <measurement group_id="O2" value="75.00"/>
                    <measurement group_id="O3" value="38.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.00"/>
                    <measurement group_id="O2" value="8.33"/>
                    <measurement group_id="O3" value="23.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="16.67"/>
                    <measurement group_id="O3" value="15.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="7.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="15.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5645</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perceived HIV Risk Reduction at Week 4: Willingness to Take a Chance of Getting HIV Infected Because Participating in This PrEP Study</title>
        <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;I am more willing to take a chance of getting infected now that I am in this PrEP study&quot;.</description>
        <time_frame>Week 4</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived HIV Risk Reduction at Week 4: Willingness to Take a Chance of Getting HIV Infected Because Participating in This PrEP Study</title>
          <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;I am more willing to take a chance of getting infected now that I am in this PrEP study&quot;.</description>
          <population>Not all participants answered every question</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.21"/>
                    <measurement group_id="O2" value="83.33"/>
                    <measurement group_id="O3" value="94.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.26"/>
                    <measurement group_id="O2" value="5.56"/>
                    <measurement group_id="O3" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.53"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="5.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="5.56"/>
                    <measurement group_id="O3" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="5.56"/>
                    <measurement group_id="O3" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7847</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perceived HIV Risk Reduction at Week 8: Willingness to Take a Chance of Getting HIV Infected Because Participating in This PrEP Study</title>
        <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;I am more willing to take a chance of getting infected now that I am in this PrEP study&quot;.</description>
        <time_frame>Week 8</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived HIV Risk Reduction at Week 8: Willingness to Take a Chance of Getting HIV Infected Because Participating in This PrEP Study</title>
          <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;I am more willing to take a chance of getting infected now that I am in this PrEP study&quot;.</description>
          <population>Not all participants answered every question</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.75"/>
                    <measurement group_id="O2" value="100.00"/>
                    <measurement group_id="O3" value="64.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="29.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.25"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="5.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0288</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perceived HIV Risk Reduction at Week 12: Willingness to Take a Chance of Getting HIV Infected Because Participating in This PrEP Study</title>
        <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;I am more willing to take a chance of getting infected now that I am in this PrEP study&quot;.</description>
        <time_frame>Week 12</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived HIV Risk Reduction at Week 12: Willingness to Take a Chance of Getting HIV Infected Because Participating in This PrEP Study</title>
          <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;I am more willing to take a chance of getting infected now that I am in this PrEP study&quot;.</description>
          <population>Not all participants answered every question</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.00"/>
                    <measurement group_id="O2" value="93.75"/>
                    <measurement group_id="O3" value="68.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.33"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="18.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.67"/>
                    <measurement group_id="O2" value="6.25"/>
                    <measurement group_id="O3" value="12.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0945</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perceived HIV Risk Reduction at Week 16: Willingness to Take a Chance of Getting HIV Infected Because Participating in This PrEP Study</title>
        <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;I am more willing to take a chance of getting infected now that I am in this PrEP study&quot;.</description>
        <time_frame>Week 16</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived HIV Risk Reduction at Week 16: Willingness to Take a Chance of Getting HIV Infected Because Participating in This PrEP Study</title>
          <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;I am more willing to take a chance of getting infected now that I am in this PrEP study&quot;.</description>
          <population>Not all participants answered every question</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.67"/>
                    <measurement group_id="O2" value="93.33"/>
                    <measurement group_id="O3" value="71.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.00"/>
                    <measurement group_id="O2" value="6.67"/>
                    <measurement group_id="O3" value="7.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="7.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.33"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="7.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="7.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3884</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perceived HIV Risk Reduction at Week 20: Willingness to Take a Chance of Getting HIV Infected Because Participating in This PrEP Study</title>
        <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;I am more willing to take a chance of getting infected now that I am in this PrEP study&quot;.</description>
        <time_frame>Week 20</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived HIV Risk Reduction at Week 20: Willingness to Take a Chance of Getting HIV Infected Because Participating in This PrEP Study</title>
          <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;I am more willing to take a chance of getting infected now that I am in this PrEP study&quot;.</description>
          <population>Not all participants answered every question</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.67"/>
                    <measurement group_id="O2" value="92.86"/>
                    <measurement group_id="O3" value="61.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.33"/>
                    <measurement group_id="O2" value="7.14"/>
                    <measurement group_id="O3" value="30.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="7.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2235</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perceived HIV Risk Reduction at Week 24: Willingness to Take a Chance of Getting HIV Infected Because Participating in This PrEP Study</title>
        <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;I am more willing to take a chance of getting infected now that I am in this PrEP study.&quot;</description>
        <time_frame>Week 24</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived HIV Risk Reduction at Week 24: Willingness to Take a Chance of Getting HIV Infected Because Participating in This PrEP Study</title>
          <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: &quot;I am more willing to take a chance of getting infected now that I am in this PrEP study.&quot;</description>
          <population>Not all participants answered every question</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.00"/>
                    <measurement group_id="O2" value="91.67"/>
                    <measurement group_id="O3" value="53.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="23.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="23.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="8.33"/>
                    <measurement group_id="O3" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0467</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perceived HIV Risk Reduction at Week 4: Less Worried About 'Slipping up' Now That PrEP May be Taken Prior to Unprotected Sex</title>
        <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: I am a lot less worried about 'slipping up' now that PrEP may be taken prior to unprotected sex.</description>
        <time_frame>Week 4</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived HIV Risk Reduction at Week 4: Less Worried About 'Slipping up' Now That PrEP May be Taken Prior to Unprotected Sex</title>
          <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: I am a lot less worried about 'slipping up' now that PrEP may be taken prior to unprotected sex.</description>
          <population>Not all participants answered every question</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.67"/>
                    <measurement group_id="O2" value="55.56"/>
                    <measurement group_id="O3" value="55.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.56"/>
                    <measurement group_id="O2" value="27.78"/>
                    <measurement group_id="O3" value="11.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.11"/>
                    <measurement group_id="O2" value="5.56"/>
                    <measurement group_id="O3" value="16.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.11"/>
                    <measurement group_id="O2" value="5.56"/>
                    <measurement group_id="O3" value="16.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.56"/>
                    <measurement group_id="O2" value="5.56"/>
                    <measurement group_id="O3" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6331</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perceived HIV Risk Reduction at Week 8: Less Worried About 'Slipping up' Now That PrEP May be Taken Prior to Unprotected Sex</title>
        <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: I am a lot less worried about 'slipping up' now that PrEP may be taken prior to unprotected sex.</description>
        <time_frame>Week 8</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived HIV Risk Reduction at Week 8: Less Worried About 'Slipping up' Now That PrEP May be Taken Prior to Unprotected Sex</title>
          <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: I am a lot less worried about 'slipping up' now that PrEP may be taken prior to unprotected sex.</description>
          <population>Not all participants answered every question</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.06"/>
                    <measurement group_id="O2" value="66.67"/>
                    <measurement group_id="O3" value="35.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.41"/>
                    <measurement group_id="O2" value="5.56"/>
                    <measurement group_id="O3" value="35.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.65"/>
                    <measurement group_id="O2" value="27.78"/>
                    <measurement group_id="O3" value="11.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.88"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="17.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0948</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perceived HIV Risk Reduction at Week 12: Less Worried About 'Slipping up' Now That PrEP May be Taken Prior to Unprotected Sex</title>
        <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: I am a lot less worried about 'slipping up' now that PrEP may be taken prior to unprotected sex.</description>
        <time_frame>Week 12</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived HIV Risk Reduction at Week 12: Less Worried About 'Slipping up' Now That PrEP May be Taken Prior to Unprotected Sex</title>
          <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: I am a lot less worried about 'slipping up' now that PrEP may be taken prior to unprotected sex.</description>
          <population>Not all participants answered every question</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.29"/>
                    <measurement group_id="O2" value="68.75"/>
                    <measurement group_id="O3" value="43.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="12.50"/>
                    <measurement group_id="O3" value="18.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.43"/>
                    <measurement group_id="O2" value="12.50"/>
                    <measurement group_id="O3" value="18.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.29"/>
                    <measurement group_id="O2" value="6.25"/>
                    <measurement group_id="O3" value="18.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5826</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perceived HIV Risk Reduction at Week 16: Less Worried About 'Slipping up' Now That PrEP May be Taken Prior to Unprotected Sex</title>
        <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: I am a lot less worried about 'slipping up' now that PrEP may be taken prior to unprotected sex.</description>
        <time_frame>Week 16</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived HIV Risk Reduction at Week 16: Less Worried About 'Slipping up' Now That PrEP May be Taken Prior to Unprotected Sex</title>
          <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: I am a lot less worried about 'slipping up' now that PrEP may be taken prior to unprotected sex.</description>
          <population>Not all participants answered every question</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.85"/>
                    <measurement group_id="O2" value="93.33"/>
                    <measurement group_id="O3" value="42.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.38"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="42.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.08"/>
                    <measurement group_id="O2" value="6.67"/>
                    <measurement group_id="O3" value="7.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.69"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="7.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0087</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perceived HIV Risk Reduction at Week 20: Less Worried About 'Slipping up' Now That PrEP May be Taken Prior to Unprotected Sex</title>
        <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: I am a lot less worried about 'slipping up' now that PrEP may be taken prior to unprotected sex.</description>
        <time_frame>Week 20</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived HIV Risk Reduction at Week 20: Less Worried About 'Slipping up' Now That PrEP May be Taken Prior to Unprotected Sex</title>
          <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: I am a lot less worried about 'slipping up' now that PrEP may be taken prior to unprotected sex.</description>
          <population>Not all participants answered every question</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.00"/>
                    <measurement group_id="O2" value="78.57"/>
                    <measurement group_id="O3" value="38.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.00"/>
                    <measurement group_id="O2" value="7.14"/>
                    <measurement group_id="O3" value="15.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="7.14"/>
                    <measurement group_id="O3" value="15.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="7.14"/>
                    <measurement group_id="O3" value="23.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="7.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1934</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perceived HIV Risk Reduction at Week 24: Less Worried About 'Slipping up' Now That PrEP May be Taken Prior to Unprotected Sex</title>
        <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: I am a lot less worried about 'slipping up' now that PrEP may be taken prior to unprotected sex.</description>
        <time_frame>Week 24</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived HIV Risk Reduction at Week 24: Less Worried About 'Slipping up' Now That PrEP May be Taken Prior to Unprotected Sex</title>
          <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: I am a lot less worried about 'slipping up' now that PrEP may be taken prior to unprotected sex.</description>
          <population>Not all participants answered every question</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.00"/>
                    <measurement group_id="O2" value="83.33"/>
                    <measurement group_id="O3" value="46.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.00"/>
                    <measurement group_id="O2" value="16.67"/>
                    <measurement group_id="O3" value="15.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="23.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="15.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2146</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perceived HIV Risk Reduction at Week 4: Less Worried About Having Unprotected Sex Due to the Availability of PrEP</title>
        <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: The availability of PrEP makes me less worried about having unprotected sex.</description>
        <time_frame>Week 4</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived HIV Risk Reduction at Week 4: Less Worried About Having Unprotected Sex Due to the Availability of PrEP</title>
          <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: The availability of PrEP makes me less worried about having unprotected sex.</description>
          <population>Not all participants answered every question</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.16"/>
                    <measurement group_id="O2" value="66.67"/>
                    <measurement group_id="O3" value="55.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.26"/>
                    <measurement group_id="O2" value="16.67"/>
                    <measurement group_id="O3" value="27.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.53"/>
                    <measurement group_id="O2" value="5.56"/>
                    <measurement group_id="O3" value="5.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.05"/>
                    <measurement group_id="O2" value="11.11"/>
                    <measurement group_id="O3" value="5.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="5.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5317</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perceived HIV Risk Reduction at Week 8: Less Worried About Having Unprotected Sex Due to the Availability of PrEP</title>
        <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: The availability of PrEP makes me less worried about having unprotected sex.</description>
        <time_frame>Week 8</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived HIV Risk Reduction at Week 8: Less Worried About Having Unprotected Sex Due to the Availability of PrEP</title>
          <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: The availability of PrEP makes me less worried about having unprotected sex.</description>
          <population>Not all participants answered every question</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.82"/>
                    <measurement group_id="O2" value="66.67"/>
                    <measurement group_id="O3" value="35.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.65"/>
                    <measurement group_id="O2" value="11.11"/>
                    <measurement group_id="O3" value="23.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.65"/>
                    <measurement group_id="O2" value="16.67"/>
                    <measurement group_id="O3" value="11.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="5.56"/>
                    <measurement group_id="O3" value="29.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.88"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1733</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perceived HIV Risk Reduction at Week 12: Less Worried About Having Unprotected Sex Due to the Availability of PrEP</title>
        <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: The availability of PrEP makes me less worried about having unprotected sex.</description>
        <time_frame>Week 12</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived HIV Risk Reduction at Week 12: Less Worried About Having Unprotected Sex Due to the Availability of PrEP</title>
          <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: The availability of PrEP makes me less worried about having unprotected sex.</description>
          <population>Not all participants answered every question</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.33"/>
                    <measurement group_id="O2" value="81.25"/>
                    <measurement group_id="O3" value="43.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.00"/>
                    <measurement group_id="O2" value="6.25"/>
                    <measurement group_id="O3" value="18.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.67"/>
                    <measurement group_id="O2" value="6.25"/>
                    <measurement group_id="O3" value="25.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="12.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="6.25"/>
                    <measurement group_id="O3" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1747</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perceived HIV Risk Reduction at Week 16: Less Worried About Having Unprotected Sex Due to the Availability of PrEP</title>
        <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: The availability of PrEP makes me less worried about having unprotected sex.</description>
        <time_frame>Week 16</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived HIV Risk Reduction at Week 16: Less Worried About Having Unprotected Sex Due to the Availability of PrEP</title>
          <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: The availability of PrEP makes me less worried about having unprotected sex.</description>
          <population>Not all participants answered every question</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.33"/>
                    <measurement group_id="O2" value="80.00"/>
                    <measurement group_id="O3" value="35.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.33"/>
                    <measurement group_id="O2" value="6.67"/>
                    <measurement group_id="O3" value="21.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.33"/>
                    <measurement group_id="O2" value="13.33"/>
                    <measurement group_id="O3" value="28.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="14.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1203</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perceived HIV Risk Reduction at Week 20: Less Worried About Having Unprotected Sex Due to the Availability of PrEP</title>
        <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: The availability of PrEP makes me less worried about having unprotected sex.</description>
        <time_frame>Week 20</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived HIV Risk Reduction at Week 20: Less Worried About Having Unprotected Sex Due to the Availability of PrEP</title>
          <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: The availability of PrEP makes me less worried about having unprotected sex.</description>
          <population>Not all participants answered every question</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.67"/>
                    <measurement group_id="O2" value="78.57"/>
                    <measurement group_id="O3" value="53.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.00"/>
                    <measurement group_id="O2" value="14.29"/>
                    <measurement group_id="O3" value="23.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.33"/>
                    <measurement group_id="O2" value="7.14"/>
                    <measurement group_id="O3" value="15.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="7.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8243</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perceived HIV Risk Reduction at Week 24: Less Worried About Having Unprotected Sex Due to the Availability of PrEP</title>
        <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: The availability of PrEP makes me less worried about having unprotected sex.</description>
        <time_frame>Week 24</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived HIV Risk Reduction at Week 24: Less Worried About Having Unprotected Sex Due to the Availability of PrEP</title>
          <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: The availability of PrEP makes me less worried about having unprotected sex.</description>
          <population>Not all participants answered every question</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.00"/>
                    <measurement group_id="O2" value="83.33"/>
                    <measurement group_id="O3" value="53.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.00"/>
                    <measurement group_id="O2" value="8.33"/>
                    <measurement group_id="O3" value="15.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.00"/>
                    <measurement group_id="O2" value="8.33"/>
                    <measurement group_id="O3" value="15.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="15.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6202</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perceived HIV Risk Reduction at Week 4: Less Concerned About Unprotected Anal Sex Because Participating in This PrEP Study</title>
        <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: I am less concerned about having unprotected anal sex now that I am in this PrEP study.</description>
        <time_frame>Week 4</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived HIV Risk Reduction at Week 4: Less Concerned About Unprotected Anal Sex Because Participating in This PrEP Study</title>
          <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: I am less concerned about having unprotected anal sex now that I am in this PrEP study.</description>
          <population>Not all participants answered every question</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.89"/>
                    <measurement group_id="O2" value="66.67"/>
                    <measurement group_id="O3" value="50.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.32"/>
                    <measurement group_id="O2" value="22.22"/>
                    <measurement group_id="O3" value="27.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.79"/>
                    <measurement group_id="O2" value="5.56"/>
                    <measurement group_id="O3" value="16.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="5.56"/>
                    <measurement group_id="O3" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="5.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8351</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perceived HIV Risk Reduction at Week 8: Less Concerned About Unprotected Anal Sex Because Participating in This PrEP Study</title>
        <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: I am less concerned about having unprotected anal sex now that I am in this PrEP study.</description>
        <time_frame>Week 8</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived HIV Risk Reduction at Week 8: Less Concerned About Unprotected Anal Sex Because Participating in This PrEP Study</title>
          <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: I am less concerned about having unprotected anal sex now that I am in this PrEP study.</description>
          <population>Not all participants answered every question</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.06"/>
                    <measurement group_id="O2" value="83.33"/>
                    <measurement group_id="O3" value="35.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.53"/>
                    <measurement group_id="O2" value="11.11"/>
                    <measurement group_id="O3" value="41.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.53"/>
                    <measurement group_id="O2" value="5.56"/>
                    <measurement group_id="O3" value="23.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.88"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0484</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perceived HIV Risk Reduction at Week 12: Less Concerned About Unprotected Anal Sex Because Participating in This PrEP Study</title>
        <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: I am less concerned about having unprotected anal sex now that I am in this PrEP study.</description>
        <time_frame>Week 12</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived HIV Risk Reduction at Week 12: Less Concerned About Unprotected Anal Sex Because Participating in This PrEP Study</title>
          <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: I am less concerned about having unprotected anal sex now that I am in this PrEP study.</description>
          <population>Not all participants answered every question</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.14"/>
                    <measurement group_id="O2" value="81.25"/>
                    <measurement group_id="O3" value="50.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.57"/>
                    <measurement group_id="O2" value="12.50"/>
                    <measurement group_id="O3" value="18.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.14"/>
                    <measurement group_id="O2" value="6.25"/>
                    <measurement group_id="O3" value="25.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.14"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="6.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4207</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perceived HIV Risk Reduction at Week 16: Less Concerned About Unprotected Anal Sex Because Participating in This PrEP Study</title>
        <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: I am less concerned about having unprotected anal sex now that I am in this PrEP study.</description>
        <time_frame>Week 16</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived HIV Risk Reduction at Week 16: Less Concerned About Unprotected Anal Sex Because Participating in This PrEP Study</title>
          <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: I am less concerned about having unprotected anal sex now that I am in this PrEP study.</description>
          <population>Not all participants answered every question</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.00"/>
                    <measurement group_id="O2" value="80.00"/>
                    <measurement group_id="O3" value="42.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.00"/>
                    <measurement group_id="O2" value="6.67"/>
                    <measurement group_id="O3" value="28.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="13.33"/>
                    <measurement group_id="O3" value="14.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="7.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="7.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2187</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perceived HIV Risk Reduction at Week 20: Less Concerned About Unprotected Anal Sex Because Participating in This PrEP Study</title>
        <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: I am less concerned about having unprotected anal sex now that I am in this PrEP study.</description>
        <time_frame>Week 20</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived HIV Risk Reduction at Week 20: Less Concerned About Unprotected Anal Sex Because Participating in This PrEP Study</title>
          <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: I am less concerned about having unprotected anal sex now that I am in this PrEP study.</description>
          <population>Not all participants answered every question</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.00"/>
                    <measurement group_id="O2" value="92.86"/>
                    <measurement group_id="O3" value="61.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.67"/>
                    <measurement group_id="O2" value="7.14"/>
                    <measurement group_id="O3" value="23.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="7.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.33"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="7.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5369</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perceived HIV Risk Reduction at Week 24: Less Concerned About Unprotected Anal Sex Because Participating in This PrEP Study</title>
        <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: I am less concerned about having unprotected anal sex now that I am in this PrEP study.</description>
        <time_frame>Week 24</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived HIV Risk Reduction at Week 24: Less Concerned About Unprotected Anal Sex Because Participating in This PrEP Study</title>
          <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: I am less concerned about having unprotected anal sex now that I am in this PrEP study.</description>
          <population>Not all participants answered every question</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.00"/>
                    <measurement group_id="O2" value="83.33"/>
                    <measurement group_id="O3" value="46.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.00"/>
                    <measurement group_id="O2" value="16.67"/>
                    <measurement group_id="O3" value="15.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="23.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="7.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="7.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1524</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perceived HIV Risk Reduction at Week 4: Participant Has Already Risked Getting HIV Infected Through Unprotected Sex While on This PrEP Study</title>
        <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: I have already risked getting infected with HIV through unsafe sex while Ive been in this study.</description>
        <time_frame>Week 4</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived HIV Risk Reduction at Week 4: Participant Has Already Risked Getting HIV Infected Through Unprotected Sex While on This PrEP Study</title>
          <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: I have already risked getting infected with HIV through unsafe sex while Ive been in this study.</description>
          <population>Not all participants answered every question</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.16"/>
                    <measurement group_id="O2" value="50.00"/>
                    <measurement group_id="O3" value="44.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.26"/>
                    <measurement group_id="O2" value="16.67"/>
                    <measurement group_id="O3" value="5.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.53"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="22.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.05"/>
                    <measurement group_id="O2" value="27.78"/>
                    <measurement group_id="O3" value="22.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="5.56"/>
                    <measurement group_id="O3" value="5.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4700</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perceived HIV Risk Reduction at Week 8: Participant Has Already Risked Getting HIV Infected Through Unprotected Sex While on This PrEP Study</title>
        <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: I have already risked getting infected with HIV through unsafe sex while Ive been in this study.</description>
        <time_frame>Week 8</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived HIV Risk Reduction at Week 8: Participant Has Already Risked Getting HIV Infected Through Unprotected Sex While on This PrEP Study</title>
          <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: I have already risked getting infected with HIV through unsafe sex while Ive been in this study.</description>
          <population>Not all participants answered every question</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.94"/>
                    <measurement group_id="O2" value="61.11"/>
                    <measurement group_id="O3" value="23.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.88"/>
                    <measurement group_id="O2" value="11.11"/>
                    <measurement group_id="O3" value="17.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.65"/>
                    <measurement group_id="O2" value="5.56"/>
                    <measurement group_id="O3" value="23.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.88"/>
                    <measurement group_id="O2" value="5.56"/>
                    <measurement group_id="O3" value="17.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.65"/>
                    <measurement group_id="O2" value="16.67"/>
                    <measurement group_id="O3" value="17.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4686</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perceived HIV Risk Reduction at Week 12: Participant Has Already Risked Getting HIV Infected Through Unprotected Sex While on This PrEP Study</title>
        <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: I have already risked getting infected with HIV through unsafe sex while Ive been on this study.</description>
        <time_frame>Week 12</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived HIV Risk Reduction at Week 12: Participant Has Already Risked Getting HIV Infected Through Unprotected Sex While on This PrEP Study</title>
          <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: I have already risked getting infected with HIV through unsafe sex while Ive been on this study.</description>
          <population>Not all participants answered every question</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.67"/>
                    <measurement group_id="O2" value="68.75"/>
                    <measurement group_id="O3" value="25.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.33"/>
                    <measurement group_id="O2" value="6.25"/>
                    <measurement group_id="O3" value="25.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.33"/>
                    <measurement group_id="O2" value="18.75"/>
                    <measurement group_id="O3" value="18.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.33"/>
                    <measurement group_id="O2" value="6.25"/>
                    <measurement group_id="O3" value="18.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.33"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="12.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3791</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perceived HIV Risk Reduction at Week 16: Participant Has Already Risked Getting HIV Infected Through Unprotected Sex While on This PrEP Study</title>
        <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: I have already risked getting infected with HIV through unsafe sex while Ive been in this study.</description>
        <time_frame>Week 16</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived HIV Risk Reduction at Week 16: Participant Has Already Risked Getting HIV Infected Through Unprotected Sex While on This PrEP Study</title>
          <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: I have already risked getting infected with HIV through unsafe sex while Ive been in this study.</description>
          <population>Not all participants answered every question</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.15"/>
                    <measurement group_id="O2" value="66.67"/>
                    <measurement group_id="O3" value="42.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.38"/>
                    <measurement group_id="O2" value="6.67"/>
                    <measurement group_id="O3" value="14.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.38"/>
                    <measurement group_id="O2" value="6.67"/>
                    <measurement group_id="O3" value="7.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.69"/>
                    <measurement group_id="O2" value="20.00"/>
                    <measurement group_id="O3" value="21.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.38"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="14.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7374</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perceived HIV Risk Reduction at Week 20: Participant Has Already Risked Getting HIV Infected Through Unprotected Sex While on This PrEP Study</title>
        <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: I have already risked getting infected with HIV through unsafe sex while Ive been in this study.</description>
        <time_frame>Week 20</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived HIV Risk Reduction at Week 20: Participant Has Already Risked Getting HIV Infected Through Unprotected Sex While on This PrEP Study</title>
          <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: I have already risked getting infected with HIV through unsafe sex while Ive been in this study.</description>
          <population>Not all participants answered every question</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.00"/>
                    <measurement group_id="O2" value="71.43"/>
                    <measurement group_id="O3" value="61.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.33"/>
                    <measurement group_id="O2" value="21.43"/>
                    <measurement group_id="O3" value="15.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.33"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="7.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="7.14"/>
                    <measurement group_id="O3" value="7.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.33"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="7.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9363</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perceived HIV Risk Reduction at Week 24: Participant Has Already Risked Getting HIV Infected Through Unprotected Sex While on This PrEP Study</title>
        <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: I have already risked getting infected with HIV through unsafe sex while Ive been in this study.</description>
        <time_frame>Week 24</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived HIV Risk Reduction at Week 24: Participant Has Already Risked Getting HIV Infected Through Unprotected Sex While on This PrEP Study</title>
          <description>Participants were asked to state whether or not they strongly disagreed, disagreed, were neutral, agreed, or strongly agreed with the following statement: I have already risked getting infected with HIV through unsafe sex while Ive been in this study.</description>
          <population>Not all participants answered every question</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.00"/>
                    <measurement group_id="O2" value="66.67"/>
                    <measurement group_id="O3" value="30.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.00"/>
                    <measurement group_id="O2" value="16.67"/>
                    <measurement group_id="O3" value="15.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.00"/>
                    <measurement group_id="O2" value="8.33"/>
                    <measurement group_id="O3" value="15.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.00"/>
                    <measurement group_id="O2" value="8.33"/>
                    <measurement group_id="O3" value="30.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="7.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6267</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting No High-Risk Man With Man Sex Acts at Week 4</title>
        <description>A high-risk sex act was defined as an answer of greater than 0 to any of the following questions:
With your male HIV positive male partners during the past month:
How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom? How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom?</description>
        <time_frame>Week 4</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and Tenofovir (TDf) Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting No High-Risk Man With Man Sex Acts at Week 4</title>
          <description>A high-risk sex act was defined as an answer of greater than 0 to any of the following questions:
With your male HIV positive male partners during the past month:
How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom? How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom?</description>
          <population>Not all participants answered every question</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6434</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting No High-Risk Man With Man Sex Acts at Week 8</title>
        <description>A high-risk sex act was defined as an answer of greater than 0 to any of the following questions:
With your male HIV positive male partners during the past month:
How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom? How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom?</description>
        <time_frame>Week 8</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and Tenofovir (TDf) Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting No High-Risk Man With Man Sex Acts at Week 8</title>
          <description>A high-risk sex act was defined as an answer of greater than 0 to any of the following questions:
With your male HIV positive male partners during the past month:
How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom? How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom?</description>
          <population>Not all participants answered every question</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8582</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting No High-Risk Man With Man Sex Acts at Week 12</title>
        <description>A high-risk sex act was defined as an answer of greater than 0 to any of the following questions:
With your male HIV positive male partners during the past month:
How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom? How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom?</description>
        <time_frame>Week 12</time_frame>
        <population>Not all participants answered every question.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and Tenofovir (TDf) Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting No High-Risk Man With Man Sex Acts at Week 12</title>
          <description>A high-risk sex act was defined as an answer of greater than 0 to any of the following questions:
With your male HIV positive male partners during the past month:
How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom? How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom?</description>
          <population>Not all participants answered every question.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5778</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting No High-Risk Man With Man Sex Acts at Week 16</title>
        <description>A high-risk sex act was defined as an answer of greater than 0 to any of the following questions:
With your male HIV positive male partners during the past month:
How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom? How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom?</description>
        <time_frame>Week 16</time_frame>
        <population>Not all participants answered every question.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and Tenofovir (TDf) Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting No High-Risk Man With Man Sex Acts at Week 16</title>
          <description>A high-risk sex act was defined as an answer of greater than 0 to any of the following questions:
With your male HIV positive male partners during the past month:
How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom? How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom?</description>
          <population>Not all participants answered every question.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9881</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting No High-Risk Man With Man Sex Acts at Week 20</title>
        <description>A high-risk sex act was defined as an answer of greater than 0 to any of the following questions:
With your male HIV positive male partners during the past month:
How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom? How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom?</description>
        <time_frame>Week 20</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and Tenofovir (TDf) Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting No High-Risk Man With Man Sex Acts at Week 20</title>
          <description>A high-risk sex act was defined as an answer of greater than 0 to any of the following questions:
With your male HIV positive male partners during the past month:
How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom? How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom?</description>
          <population>Not all participants answered every question</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9771</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting No High-Risk Man With Man Sex Acts at Week 24</title>
        <description>A high-risk sex act was defined as an answer of greater than 0 to any of the following questions:
With your male HIV positive male partners during the past month:
How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom? How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom?</description>
        <time_frame>Week 24</time_frame>
        <population>Not all participants answered every question</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/TDF as PrEP</title>
            <description>Blinded treatment with FTC (Emtricitabine) and Tenofovir (TDf) Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill Control</title>
            <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>No Pill Control</title>
            <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting No High-Risk Man With Man Sex Acts at Week 24</title>
          <description>A high-risk sex act was defined as an answer of greater than 0 to any of the following questions:
With your male HIV positive male partners during the past month:
How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom? How many times did you have insertive anal sex WITHOUT a condom? How many times did you have receptive anal sex WITHOUT a condom?</description>
          <population>Not all participants answered every question</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2301</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>FTC/TDC</title>
          <description>Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
Coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Blinded administration of placebo pill; HIV behavioral intervention
Placebo: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
        </group>
        <group group_id="E3">
          <title>No Pill Control</title>
          <description>Subjects receive HIV behavioral intervention but no pill.
Many Men, Many Voices (3MV): Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Bilirubin Increased</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Protein Urine Present</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Creatinine Renal Clearance Decreased</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Adolescent Medicine Trials Network (ATN) for HIV/AIDS Interventions Publication Policy outlines procedures for the development and review of abstracts, publications and presentations. The Adolescent Medicine Leadership Group (AMLG) retains custody of and primary rights to the data. Use of data must be approved by the protocol team and AMLG.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>After release of Pre-exposure Prophylaxis Initiative efficacy results, the Data and Safety Monitoring Board recommended that subjects be unblinded, enrollment stopped, all be offered option of PrEP, subjects on PrEP arm continued as scheduled.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Bob Harris</name_or_title>
      <organization>Westat</organization>
      <phone>301-251-1500</phone>
      <email>bobharris@westat.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

